Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?

Liver International

Volumn 33, Issue 3, 2013, Pages 488-493

  Brandi, Giovanni ^a   De Rosa, Francesco ^a   Calzà, Laura ^a   Girolamo, Stefania Di ^a   Tufoni, Manuel ^a   Ricci, Carmen Serena ^a   Cirignotta, Fabio ^b   Caraceni, Paolo ^a   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cognitive impairment; Hepatocellular carcinoma; Metabolic encephalopathy; Sorafenib; Tyrosine kinase inhibitors

Indexed keywords

CANRENOATE POTASSIUM; LACTULOSE; RIFAXIMIN; SORAFENIB; TORASEMIDE;

AGED; AMNESIA; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PATIENT; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC ENCEPHALOPATHY; METASTASIS; MOOD DISORDER; RETROSPECTIVE STUDY;

AGED; BRAIN DISEASES, METABOLIC; CARCINOMA, HEPATOCELLULAR; COGNITION DISORDERS; ELECTROENCEPHALOGRAPHY; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MOOD DISORDERS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873715598     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12102     Document Type: Article

References (31)

1. Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
3. Poon RTP. Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: transplantation or resection? Ann Surg Oncol 2007; 14: 541-7.
4. Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Méndez-Sánchez N, Vásquez-Fernández F, Zamora-Valdés D, Uribe M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Hepatol 2008; 7: 46-51.
7. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010; 15: 130-41.
8. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-48.
9. Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol 2010; 27: 1436-7.
10. Chen A, Agarwal N. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J 2009; 39: 341-2.
11. Hadj JO, Braven RD, Tillier C, et al. Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncol Lett 2012; 3: 1293-6.
12. Chelis L, Souftas V, Amarantidis K, et al. Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer 2012; 12: 489.
13. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354: 980-2.
14. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006; 24: e48.
15. Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what's certain, what's new? Pract Neurol 2011; 11: 136-44.
16. Lee N-R, Yhim H-Y, Yim C-Y, Kwak J-Y, Song E-K. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors. Ann Pharmacother 2011; 45: e56.
17. Okyuama T, Akazawa Y, Uchida J, et al. Subacute transient encephalopathy induced by erlotinib. Oncol Res 2011; 19: 399-402.
18. Marks AB, Gerard R, Fournier P, Coupe P, Gautier S. Sorafenib-induced hepatic encephalopathy. Ann Pharmacother 2009; 43: 2121.
19. Córdoba J. New assessment of hepatic encephalopathy. J Hepatol 2011; 54: 1030-40.
20. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-65.
21. Adams RD, Foley JM. The neurological disorder associated with liver disease. Res Publ Assoc Res Nerv Ment Dis 1953; 32: 198-237.
22. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
23. Blanco Vela CI, Bosques Padilla FJ. Determination of ammonia concentrations in cirrhosis patients-still confusing after all these years? Ann Hepatol 2011; 10(Suppl. 2): S60-5.
24. Kim E-J, Monje FJ, Li L, et al. Alzheimer's disease risk factor lymphocyte-specific protein tyrosine kinase regulates long-term synaptic strengthening, spatial learning and memory. Cell Mol Life Sci 2012; doi:10.1007/s00018-012-1168-1 [Epub ahead of print].
25. Counts SE, Nadeem M, Wuu J, et al. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 2004; 56: 520-31.
26. Liu Y-F, Chen H, Yu L, et al. Upregulation of hippocampal TrkB and synaptotagmin is involved in treadmill exercise-enhanced aversive memory in mice. Neurobiol Learn Mem 2008; 90: 81-9.
27. Zhao W-Q, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004; 490: 71-81.
28. Ling DSF, Benardo LS, Serrano PA, et al. Protein kinase Mzeta is necessary and sufficient for LTP maintenance. Nat Neurosci 2002; 5: 295-6.
29. Nelson TJ, Sun M-K, Hongpaisan J, Alkon DL. Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol 2008; 585: 76-87.
30. Ferguson SS. Receptor tyrosine kinase transactivation: fine-tuning synaptic transmission. Trends Neurosci 2003; 26: 119-22.
31. Zamora Nava LE, Torre Delgadillo A. Minimal hepatic encephalopathy. Ann Hepatol 2011; 10(Suppl. 2): S50-4.